Revolution Medicines starts Phase 3 first-line pancreatic cancer combination trial
Revolution Medicines has started enrolling patients in RASolute 309, a global randomized Phase 3 study in metastatic RAS G12D pancreatic adenocarcinoma. The study tests RASONQUE, or daraxonrasib, with investigational drug zoldonrasib as an initial treatment against gemcitabine plus nab-paclitaxel. Its co-primary measures are progression-free survival and overall survival.
Why it matters
The trial moves Revolution Medicines' RASONQUE-zoldonrasib combination into a late-stage first-line setting. The company says earlier clinical findings in previously treated metastatic disease showed antitumor activity with manageable safety, but the Phase 3 study will determine comparative efficacy and survival outcomes.
Key facts
- 1Revolution Medicines began treating patients in the global randomized, open-label Phase 3 RASolute 309 trial on Oct. 05, 2026. globenewswire.com
- 2RASolute 309 compares RASONQUE plus zoldonrasib with gemcitabine and nab-paclitaxel for adults receiving first-line treatment for metastatic RAS G12D pancreatic adenocarcinoma. globenewswire.com
- 3The study's dual primary endpoints are progression-free survival and overall survival. globenewswire.com
- 4RASolute 309 is identified as NCT07805954. globenewswire.com
- 5RASONQUE received U.S. FDA approval in August 2026 for certain adults with metastatic pancreatic adenocarcinoma. investing.com
- 6Zoldonrasib remains investigational and has no regulatory approvals, according to the report. investing.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.